Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress
Main Content

Parallel Session 3407

The Role of a-synuclein and Other Proteins in Parkinson’s Disease Pathogenesis

Tuesday, October 7, 2025
16:30 - 18:00 | Room TBD

In this session, the faculty will discuss the molecular pathomechanisms and the spectrum of proteins involved in Parkinson’s disease, as well as the implications for clinical trials.


Chairs:

Gabor Kovacs, Canada
Per Svenningsson, Sweden

Presenters:

A-Synuclein Prion Strains in Parkinson's Disease Pathogenesis, Phenotype, and Progression
Ayami Okuzumi, Japan

Proteins Beyond A-synuclein: Bystanders or Real Partners?
Zane Jaunmuktane, United Kingdom

Clinical Implications of Co-pathologies
Bradley Boeve, USA

CSPC Liaisons:

Gabor Kovacs, Canada

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Interpret the role of a-synuclein prion strains in the pathogenesis, phenotypic spectrum and disease progression in Parkinson’s disease
  2. Recognize the spectrum of proteins involved beyond a-synuclein in the pathogenesis of Parkinson’s disease
  3. Interpret the relevance of mixed pathologies in patient selection and clinical trial design

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Intermediate / Experienced

Focus

Basic Science
Translational